Evidence map›Paper›PMID 29717190›Full record

ArticleNature reviews. Nephrology2018

Rethinking progression of CKD as a process of punctuated equilibrium.

Richard J Johnson, Bernardo Rodriguez-Iturbe

Abstract read
PubMed Publisher
In one paragraph

Article in Nature reviews. Nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2-lessons from evolution, the animal kingdom and rare progeroid syndromes.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Review
  4. The transition clinic in chronic kidney disease care.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richard J JohnsonDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. richard.johnson@ucdenver.edu.
Bernardo Rodriguez-IturbeNephrology Service Hospital Universitario, Universidad del Zulia, Instituto Venezolano de Investigaciones Científicas (IVIC-Zulia), Maracaibo, Venezuela.

Funding

Targeting fructokinase, endogenous fructose production and purine degradation for the prevention and treatment of hereditary fructose intoleranceR01DK108859 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Miguel Angel Lanaspa Garcia · 2016 to 2026
$2.4M
Novel Insulin-Independent Gluco-Regulatory MechanismsR01DK109408 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BERGLUND, ERIC · 2016 to 2020
$1.8M
NIDDK NIH HHS R01 DK108859NIDDK NIH HHS R01 DK109408
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionAcute Kidney InjuryDiabetes Mellitus, Type 2Glomerular Filtration RateHumansHypertensionRenal Insufficiency, ChronicRenin-Angiotensin System

Identifiers

PMID29717190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.